Welcome to our dedicated page for Applied Dna Scie news (Ticker: APDN), a resource for investors and traders seeking the latest updates and insights on Applied Dna Scie stock.
Applied DNA Sciences, Inc. (APDN) delivers innovative synthetic DNA solutions for therapeutic development, molecular diagnostics, and supply chain security. This news hub provides investors and industry professionals with centralized access to official corporate announcements and verified updates.
Track critical developments across the company's core operations, including advancements in PCR-based DNA production, diagnostic testing services, and anti-counterfeiting technologies. Our curated feed features earnings reports, strategic partnerships, product launches, and regulatory milestones that impact APDN's market position.
Key focus areas include updates on the Linea DNA platform for mRNA therapeutics, CertainT forensic authentication solutions, and clinical testing services. Users benefit from timestamped press releases organized chronologically while maintaining factual accuracy and regulatory compliance.
Bookmark this page for direct access to Applied DNA Sciences' latest financial disclosures, technology patents, and supply chain security initiatives. Check regularly for updates on nucleic acid manufacturing innovations and DNA-based brand protection programs shaping the biotechnology sector.
Applied DNA Sciences' (NASDAQ:APDN) subsidiary LineaRx has completed its transition to a U.S.-based supply chain for critical input materials used in its LineaDNA™ and LineaIVT™ platforms. This strategic move, responding to the 2024 BIOSECURE Act and customer demand, positions the company to support the reshoring of biopharmaceutical manufacturing operations in the United States.
As the largest PCR-based cell-free DNA producer in the U.S., LineaRx now sources over 75% of its manufacturing cost components domestically, including DNA template materials and manufacturing enzymes. The company's proprietary PCR-based platform enables rapid production of high-fidelity, cell-free DNA in quantities from milligram to multi-gram scale for genetic medicines development.
Applied DNA Sciences (NASDAQ:APDN) has successfully regained compliance with Nasdaq's minimum bid price requirement. The company, which specializes in PCR-based DNA technologies, received confirmation from Nasdaq's Listing Qualifications Department on April 7, 2025.
The company had previously fallen out of compliance on November 12, 2024, when it failed to maintain the required minimum bid price of $1.00 over 30 consecutive business days. To rectify this situation, APDN needed to maintain a closing bid price of at least $1.00 for a minimum of 10 consecutive business days.
The company exceeded this requirement by maintaining the minimum bid price for 16 consecutive business days, from March 14 through April 4, 2025. With this achievement, Nasdaq has confirmed the matter is now closed.
Applied DNA Sciences (NASDAQ:APDN) is repositioning its TR8™ PGx pharmacogenomics testing service to focus on specific use cases, starting with pre-emptive testing for DPYD gene variants. This initiative follows an FDA safety announcement regarding patients with DPYD genetic variants who may experience severe toxicities when taking fluoropyrimidine-based cancer drugs.
The company's TR8 PGx test, approved by the New York State Department of Health, can identify individuals with DPYD genotypes affecting DPD enzyme activity, important for metabolizing drugs like capecitabine and fluorouracil (5-FU). These medications, with approximately 924,000 prescriptions in 2022, are commonly used in treating various cancers including colorectal, breast, and cervical.
Statistics show that about 1 in 1,000 patients carry two DPYD gene variants causing DPD enzyme absence, while 3-8% of the population has one variant resulting in lower enzyme levels, with higher frequency in African Americans.
Applied DNA Sciences (NASDAQ:APDN) has submitted a validation package to the New York State Department of Health for approval of its laboratory-developed test (LDT) for detecting H5 bird flu. The company's Linea™ Avian Influenza H5 Dx assay (AIH5 Dx) is designed to detect and differentiate between pan-influenza A and H5 bird flu.
The development was initiated in January 2025 following increased concerns about H5 bird flu spread in dairy cows and poultry, along with human infections in U.S. workers. If approved, Applied DNA Clinical Labs (ADCL) will launch a testing service accepting samples from states recognizing New York's CLEP/CLIA certification.
The testing would be conducted at ADCL, an NYSDOH CLEP-permitted, CLIA-certified laboratory, adding to its existing diagnostic testing menu that includes mpox, SARS-CoV-2, and pharmacogenetic testing. The timeline for NYSDOH's review and potential approval remains uncertain.
Applied DNA Sciences (NASDAQ:APDN) has announced a 1-for-50 reverse stock split effective March 14, 2025. The split will reduce outstanding shares from approximately 55.2 million to 1.1 million, while maintaining trading on the Nasdaq Capital Market under the same symbol 'APDN'.
The reverse split follows stockholder approval granted on September 30, 2024, authorizing the Board to implement a split ratio between 1-for-5 and 1-for-50. The Board approved the maximum ratio on March 3, 2025, aiming to comply with Nasdaq's $1.00 minimum bid price requirement for continued listing.
The company will adjust proportionally all outstanding stock options, restricted stock units, and warrants. Fractional shares will be rounded up to the nearest whole share, and the $0.001 par value per share will remain unchanged.
Applied DNA Sciences (NASDAQ:APDN) reported Q1 fiscal 2025 financial results, announcing strategic restructuring initiatives. The company is exiting its DNA Tagging and Security Products business segment and implemented a 20% workforce reduction in January, expected to reduce annual payroll costs by 13% with one-time separation costs of $300,000.
Key financial highlights include revenue of $1.2 million (up 34% YoY), operating loss of $3.0 million, and net loss of $2.7 million. Cash position stands at $9.3 million as of December 31, 2024.
The company completed its GMP Site 1 facility in Stony Brook, NY, with an initial manufacturing capacity of approximately ten grams per annum, supporting potential annual revenues of $10-30 million. The facility received commercial operation certification in January 2025 and enables enzymatic manufacture of Linea DNA™ IVT templates for mRNA clinical trial materials.
Applied DNA Sciences (NASDAQ:APDN) has announced it will release its first quarter fiscal 2025 financial results after market close on Thursday, February 13, 2025. The company will host a conference call and webcast for shareholders and investors at 4:30 p.m. ET on the same day.
The conference call will be accessible via multiple channels including domestic toll-free, international, and Canadian toll-free numbers. A live webcast will be available, and an accompanying slide presentation will be embedded in both live and replay formats. A replay of the conference call will be available for 7 days following the event through various access numbers with the replay access code 7896562.
Applied DNA Sciences (NASDAQ:APDN) has issued a reminder to shareholders to cast their votes before the reconvening of a Special Meeting of Stockholders scheduled for February 14, 2025, at 11:00 a.m. The meeting, originally held on January 23, 2025, was adjourned due to lack of quorum.
The primary focus is the Warrant Exercise Proposal, which seeks approval for the exercisability of certain common stock purchase warrants and the issuance of underlying common stock. These warrants were issued during a securities offering on October 30, 2024. Shareholders of record as of November 25, 2024, who haven't yet voted can contact Kingsdale Advisors at 1-855-682-9644 or contactus@kingsdaleadvisors.com.
The proposal requires approval in accordance with Nasdaq Listing Rule 5635(d), as detailed in the Company's definitive proxy statement filed with the SEC on December 10, 2024.
Applied DNA Sciences (NASDAQ:APDN) has completed the buildout of its new Good Manufacturing Practices (GMP) facility at its Stony Brook, New York headquarters. The facility, expected to be fully operational by January's end, will manufacture LineaDNA IVT templates for mRNA clinical trial materials.
Key facility specifications include:
- Annual IVT template manufacturing capacity of ~10 grams with 100% cell-free workflow
- 10mg to gram-scale production in 6-14 weeks
- Projected revenue capacity of $10-30 million depending on product mix
- Multiple purification options and dedicated quality control areas
The company is currently negotiating a supply agreement for GMP IVT template with an mRNA therapeutic developer and reaffirmed its plan to complete strategic restructuring by quarter-end to drive sustainable growth, optimize costs, and extend cash runway.
Applied DNA Sciences (NASDAQ:APDN) has announced the rescheduling of its Investor Update call from January 9, 2025, to Thursday, February 13, 2025. The rescheduling aligns with the release of the company's first quarter fiscal 2025 financial results. The original call was intended to provide shareholders with updates on the company's strategic restructuring announced in December 2024 and GMP initiative. The schedule change is due to the observance of the National Day of Mourning in recognition of the passing of former President Jimmy Carter.
FAQ
What is the current stock price of Applied Dna Scie (APDN)?
What is the market cap of Applied Dna Scie (APDN)?
